Hemorrhagic Cystitis clinical trials at UCSF
1 research study open to eligible people
The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis
open to eligible people ages 18 years and up
The purpose of this study is to assess the safety and tolerability of three doses of LP-10 (intravesical tacrolimus). Twelve subjects meeting the inclusion and exclusion criteria will be enrolled and treated in a prospective and multi-center trial with LP-10. The proposed trial will recruit 12 subjects in a dose-escalation trial where 4 subjects will be allocated into each one of three groups.
San Francisco, California and other locations
Our lead scientists for Hemorrhagic Cystitis research studies include Benjamin Breyer, MD.